Seekamp A, van Griensven M, Dhondt E, Diefenbeck M, Demeyer I, Vundelinckx G, Haas N, Schaechinger U, Wolowicka L, Rammelt S, Stroobants J, Marzi I, Brambrink AM, Dziurdzik P, Gasiorowski J, Redl H, Beckert M, Khan-Boluki J. The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial.
Crit Care Med 2004;
32:2021-8. [PMID:
15483410 DOI:
10.1097/01.ccm.0000142396.59236.f3]
[Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE
The objectives of this study were to evaluate safety (primary) and clinical efficacy (secondary) of the humanized monoclonal anti-L-selectin antibody aselizumab in severely injured patients.
DESIGN
Prospective phase II, parallel group, double-blind, randomized, placebo-controlled clinical trial.
SETTING
Fourteen medical intensive care units or trauma units in level I trauma centers in Belgium, Germany, and Poland.
PATIENTS
Eighty-four patients with a sustained trauma due to a blunt or penetrating injury and a total Injury Severity Scale score of > or =25.
INTERVENTIONS
Patients received either aselizumab at dosages of 0.5, 1, or 2 mg/kg or placebo within 6 hrs of the traumatic event and were followed for 6 wks.
MEASUREMENTS AND MAIN RESULTS
The number of expeditable adverse events increased dose dependently over the aselizumab groups compared with placebo. There were no statistically significant differences between all groups regarding leukopenia and risk of infection. No immunologic response following infusion of aselizumab was noted. The number of patients with multiple organ failure, defined as a median value of the total Goris Multiple Organ Failure score of > or =5 on > or =2 consecutive days within 14 days, was not significantly different for the 0.5 mg/kg, 1 mg/kg, 2 mg/kg, and placebo groups. There were no statistically significant differences in time of mechanical ventilation, length of stay in an intensive care unit, and total duration of hospitalization between treatment groups.
CONCLUSIONS
Aselizumab was associated with a higher rate of infections and leucopenia; however, this difference was not significantly different compared with placebo. For all efficacy variables, aselizumab presented no significant trends but only a few scattered statistically significant differences between groups.
Collapse